RESUMO
BACKGROUND: Depression is a common mood disorder during pregnancy impacting one in every seven women. Children exposed to prenatal depression are more likely to be born at a low birth weight and develop chronic diseases later in life. A proposed hypothesis for this relationship between early exposure to adversity and poor outcomes is accelerated aging. Telomere length has been used as a biomarker of cellular aging. We used high-resolution telomere length analysis to examine the relationship between placental telomere length distributions and maternal mood symptoms in pregnancy. METHODS: This study utilised samples from the longitudinal Grown in Wales (GiW) study. Women participating in this study were recruited at their presurgical appointment prior to a term elective caesarean section (ELCS). Women completed the Edinburgh Postnatal Depression Scale (EPDS) and trait subscale of the State-Trait Anxiety Inventory (STAI). Telomere length distributions were generated using single telomere length analysis (STELA) in 109 term placenta (37-42 weeks). Multiple linear regression was performed to examine the relationship between maternally reported symptoms of depression and anxiety at term and mean placental telomere length. RESULTS: Prenatal depression symptoms were significantly negatively associated with XpYp telomere length in female placenta (B = -0.098, p = 0.026, 95% CI -0.184, -0.012). There was no association between maternal depression symptoms and telomere length in male placenta (B = 0.022, p = 0.586, 95% CI -0.059, 0.103). There was no association with anxiety symptoms and telomere length for either sex. CONCLUSION: Maternal prenatal depression is associated with sex-specific differences in term placental telomeres. Telomere shortening in female placenta may indicate accelerated placental aging.
Assuntos
Transtornos de Ansiedade/complicações , Depressão/complicações , Placenta/patologia , Encurtamento do Telômero , Transtornos de Ansiedade/psicologia , Depressão/psicologia , Feminino , Idade Gestacional , Humanos , Lactente , Masculino , Idade Materna , Placenta/metabolismo , Gravidez , Fatores SexuaisRESUMO
Shortened leukocyte and placental telomeres associated with gestational diabetes mellitus (GDM) suggest this exposure triggers telomere attrition contributing to adverse outcomes. We applied high resolution Single Telomere Length Analysis (STELA) to placenta from GDM pregnancies with different treatment pathways to determine their effectiveness at preventing telomere attrition. Differences in telomere length between control (N = 69), GDM lifestyle intervention (n = 14) and GDM treated with metformin and/or insulin (n = 17) was tested by Analysis of Covariance (ANCOVA) followed by group comparisons using Fisher's least significant difference. For male placenta only, there were differences in mean telomere length (F(2,54) = 4.98, P = 0.01) and percentage of telomeres under 5 kb (F(2,54) = 4.65, P = 0.01). Telomeres were shorter in the GDM lifestyle intervention group compared to both controls (P = 0.02) and medically treated pregnancies (P = 0.003). There were more telomeres under 5 kb in the GDM lifestyle intervention group compared to the other two groups (P = 0.03 and P = 0.004). Although further work is necessary, we suggest that early adoption of targeted medical treatment of GDM pregnancies where the fetus is known to be male may be an effective strategy for ameliorating adverse outcomes for children.
Assuntos
Diabetes Gestacional/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Insulina/uso terapêutico , Metformina/uso terapêutico , Placenta/metabolismo , Telômero/metabolismo , Adulto , Análise de Variância , Estudos de Casos e Controles , Feminino , Humanos , Masculino , Gravidez , Comportamento de Redução do Risco , Telômero/química , Encurtamento do TelômeroRESUMO
BACKGROUND: In the UK, 11.8% of expectant mothers undergo an elective caesarean section (ELCS) representing 92 000 births per annum. It is not known to what extent this procedure has an impact on mental well-being in the longer term. AIMS: To determine the prevalence and postpartum progression of anxiety and depression symptoms in women undergoing ELCS in Wales. METHOD: Prevalence of depression and anxiety were determined in women at University Hospital Wales (2015-16; n = 308) through completion of the Edinburgh Postnatal Depression Scale (EPDS; ≥13) and State-Trait Anxiety Inventory (STAI; ≥40) questionnaires 1 day prior to ELCS, and three postpartum time points for 1 year. Maternal characteristics were determined from questionnaires and, where possible, confirmed from National Health Service maternity records. RESULTS: Using these criteria the prevalence of reported depression symptoms was 14.3% (95% CI 10.9-18.3) 1 day prior to ELCS, 8.0% (95% CI 4.2-12.5) within 1 week, 8.7% (95% CI 4.2-13.8) at 10 weeks and 12.4% (95% CI 6.4-18.4) 1 year postpartum. Prevalence of reported anxiety symptoms was 27.3% (95% CI 22.5-32.4), 21.7% (95% CI 15.8-28.0), 25.3% (95% CI 18.5-32.7) and 35.1% (95% CI 26.3-44.2) at these same stages. Prenatal anxiety was not resolved after ELCS more than 1 year after delivery. CONCLUSIONS: Women undergoing ELCS experience prolonged anxiety postpartum that merits focused clinical attention. DECLARATION OF INTEREST: None.
RESUMO
AIMS: To assess the prevalence of non-Caucasian patients in hospital admissions for onset of symptomatic diabetes mellitus during the 2003-2010 period, and to analyze the characteristics differentiating them from the Caucasian population at diagnosis and 2 years later. MATERIAL AND METHODS: A retrospective, observational study. INCLUSION CRITERIA: Patients aged 18-40 years admitted for de novo symptomatic diabetes from January 2003 to October 2010. Prevalence of patients of non-Caucasian origin was analyzed, and clinical, biochemical, immunological, and beta-cell function of both populations were compared at diagnosis and 2 years later. RESULTS: Nineteen percent of patients admitted to hospital for de novo symptomatic diabetes were non-Caucasian, with a progressive increase in recent years. Non-Caucasian patients had milder decompensation (3.0% had ketoacidosis, as compared to 15.2% in the Caucasian group, P<.05), lower presence of autoimmunity (27.2 vs. 73.1%, P<.01) and higher stimulated C-peptide levels (0.70±0.56 vs. 0.42±0.39 nmol/l, P<.05), mainly because of the subgroup with negative autoimmunity (0.82 vs. 0.25). Two years after diagnosis, less non-Caucasian patients were on intensified treatment (39.1 vs. 93.8%). CONCLUSIONS: Non-Caucasian patients had a lower prevalence of autoimmunity, better beta-cell function at diagnosis, particularly due to the subgroup with negative autoimmunity, and less need for intensive treatment 2 years after diagnosis, features which are more characteristic of type 2 diabetes mellitus.
Assuntos
Diabetes Mellitus/etnologia , Admissão do Paciente/estatística & dados numéricos , Grupos Raciais/estatística & dados numéricos , Adolescente , Adulto , Autoanticorpos/sangue , Peptídeo C/sangue , Terapia Combinada , Diabetes Mellitus/epidemiologia , Diabetes Mellitus/terapia , Cetoacidose Diabética/epidemiologia , Cetoacidose Diabética/etnologia , Feminino , Seguimentos , Hospitais Universitários/estatística & dados numéricos , Humanos , Hipoglicemiantes/uso terapêutico , Células Secretoras de Insulina/metabolismo , Masculino , Prevalência , Estudos Retrospectivos , Espanha/epidemiologia , Adulto JovemRESUMO
Objetivos: Determinar la prevalencia de pacientes de origen no caucásico en los ingresos hospitalarios por inicio de diabetes mellitus durante el periodo 2003-2010 y analizar las características diferenciales respecto a la población caucásica en el momento del inicio y a los 2 años. Material y métodos: Estudio observacional retrospectivo. Criterios de inclusión: pacientes ingresados por inicio sintomático de diabetes entre enero de 2003 y octubre de 2010, con edad entre 18 y 40 años. Se analizó la prevalencia de pacientes de origen no caucásico, se compararon ambas poblaciones respecto a datos clínicos, bioquímicos, de reserva pancreática e inmunológicos en el momento del inicio y se analizó la evolución a los 2 años. Resultados: De los ingresos por inicio sintomático de diabetes, el 19% fueron pacientes no caucásicos, con un aumento progresivo en los últimos años. Estos presentaban un grado de descompensación más leve (3,0% de cetoacidosis respecto al 15,2% en el grupo caucásico, p < 0,05), menor autoinmunidad (27,2 vs. 73,1%, p < 0,01) y un péptido C estimulado mayor (0,70 ± 0,56 vs. 0,42 ± 0,39 nmol/l; p <0,05), básicamente a expensas del grupo con autoinmunidad negativa (0,82 vs. 0,25). A los 2 años del inicio, los pacientes no caucásicos tenían un menor porcentaje de tratamiento intensivo (39,1 vs. 93,8%). Conclusiones: El grupo de pacientes no caucásicos presenta menor prevalencia de autoinmunidad, mejor funcionalismo celular beta al diagnóstico, sobre todo a expensas del subgrupo de pacientes con autoinmunidad negativa, y menor necesidad de tratamiento intensivo a los 2 años del diagnóstico, comportamiento más característico de la diabetes mellitus tipo 2 (AU)
Aims:To assess the prevalence of non-Caucasian patients in hospital admissions for onset of symptomatic diabetes mellitus during the 2003-2010 period, and to analyze the characteristics differentiating them from the Caucasian population at diagnosis and 2 years later. Material and methods: A retrospective, observational study. Inclusion criteria: Patients aged 18-40 years admitted for de novo symptomatic diabetes from January 2003 to October 2010. Prevalence of patients of non-Caucasian origin was analyzed, and clinical, biochemical, immunological, and beta-cell function of both populations were compared at diagnosis and 2 years later. Results: Nineteen percent of patients admitted to hospital for de novo symptomatic diabetes were non-Caucasian, with a progressive increase in recent years. Non-Caucasian patients had milder decompensation (3.0% had ketoacidosis, as compared to 15.2% in the Caucasian group, P<.05), lower presence of autoimmunity (27.2 vs. 73.1%, P<.01) and higher stimulated C-peptide levels (0.70 ± 0.56 vs. 0.42 ± 0.39 nmol/l, P<.05), mainly because of the subgroup with negative autoimmunity (0.82 vs. 0.25). Two years after diagnosis, less non-Caucasian patients were on intensified treatment (39.1 vs. 93.8%). Conclusions: Non-Caucasian patients had a lower prevalence of autoimmunity, better beta-cell function at diagnosis, particularly due to the subgroup with negative autoimmunity, and less need for intensive treatment 2 years after diagnosis, features which are more characteristic of type 2 diabetes mellitus (AU)